Influenza Medication Market to Develop Rapidly by 2025

The global Influenza Medication Market is displaying a highly competitive business structure, finds a new research study by Transparency Market Research (TMR). Daiichi Sankyo Co., GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd. and Mylan Inc. are some of the prominent players operating in this market.

View Report -
https://www.transparencymarketresearch.com/influenza-medication-market.html

However, only a few players have acquired the leading position, making the business landscape in this market moderately consolidated. The leading vendors of influenza medication are expected to take up strategic partnerships, states the market study.

According to the research report, the global influenza medication market was worth US$1.69 bn in 2016. Expanding at a CAGR of 1.40% during the period from 2017 to 2025, the market is projected to reach US$2.01 bn by the end of the forecast period. zanamivir, oseltamivir, peramivir, amantadine, rimantadine, and inosine are the main products available in this market. Among these, the oseltamivir segment is leading the global market.

Request to View Sample of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=24038

North America and Europe to Remain Dominant

On the basis of the geography, the global market for influenza medication has been segmented into North America, Asia Pacific, Latin America, the Middle East and Africa, and Europe in this research report. Among these, the markets in North America and Europe has acquired the dominance, thanks to the presence of a better medical and healthcare infrastructure. These regional markets are anticipated to remain on the top over the next few years. The presence of leading players are likely to support these regional markets. The increasing uptake of high-cost therapies has spiked prospects for the influenza medication market in North America. The U.S. dominated the Influenza medication in North America, accounting for nearly 49.8% share in 2016. Asia Pacific and the Middle East and Africa are also expected to witness a significant rise in the years to come, states the research report.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24038

Rising Prevalence of Influenza and Infections to Support Growth

“The global influenza medication market is gaining from the increasing incidence of influenza and infections across the world,” says a TMR analyst. Besides this, the presence of favorable government policies relating to the prevention and treatment of influenza is also supporting the market’s growth trajectory. In emerging markets, such as Asia Pacific, the market for influenza is likely to gain from the rising incidence of ailments and availability of healthcare facilities at a low cost in the years to come, states the report.

Enquiry for discount on this report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=24038

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.